Evidence map›Paper›PMID 38204599›Full record

ArticleRegenerative therapy2024

Mesenchymal cells support the early retention of primary alveolar type 2 cells on acellular mouse lung scaffolds.

Daisuke Taniguchi, Mohammadali Ahmadipour, Anthony L Eiliazadeh, Pascal Duchesneau, Takeshi Nagayasu, Siba Haykal, Golnaz Karoubi, Thomas K Waddell

Abstract read
In one paragraph

Article in Regenerative therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daisuke TaniguchiLatner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.
Mohammadali AhmadipourLatner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.
Anthony L EiliazadehLatner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.
Pascal DuchesneauLatner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.
Takeshi NagayasuDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Siba HaykalLatner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.
Golnaz KaroubiLatner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.
Thomas K WaddellLatner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Tissue engineering approaches via repopulation of acellular biological grafts provide an exciting opportunity to generate lung grafts for transplantation. Alveolar type 2 (AT2) cells are a promising cell source for re-epithelialization. There are however inherent limitations with respect to their survival and growth, thus impeding their usability for tissue engineering applications. This study investigates the use of mesenchymal stromal cells to support primary AT2 cells for recellularization of mouse lung scaffolds. Methods: AT2 cells and bone marrow-derived mesenchymal cells (BMC) were co-delivered to decellularized mouse lung scaffolds. Recellularized lungs were evaluated for cell surface coverage, viability, and differentiation at 1 and 4 days after cell seeding. Recellularization was evaluated via histological analysis and immunofluorescence. Results: Simultaneous delivery of AT2 and BMC into acellular lung scaffolds resulted in enhanced cell surface coverage and reduced AT2 cell apoptosis in the recellularized scaffolds at Day 1 but not Day 4. AT2 cell number decreased after 4 days in both of AT2 only and codelivery groups suggesting limited expansion potential in the scaffold. After retention in the scaffold, AT2 cells differentiated into Aqp5-expressing cells. Conclusions: Our results indicate that BMC support AT2 cell survival during the initial attachment and engraftment phase of recellularization. While our findings suggest only a short-term beneficial effect of BMC, our study demonstrates that AT2 cells can be delivered and retained in acellular lung scaffolds; thus with preconditioning and supporting cells, may be used for re-epithelialization. Selection and characterization of appropriate cell sources for use in recellularization, will be critical for ultimate clinical application.

Indexed as

Alveolar type 2 cellsBone marrow-derived mesenchymal cellsDecellularized lung scaffoldLung regenerationRecellularization

Identifiers

PMID38204599
PMCPMC10776435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.